Skip to main content

Table 1 Cohort characteristics

From: Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study

  n (%)
Age (years)* 30.5 (± 18.7)
Sex
 Female 253 (59.7)
 Male 171 (40.3)
Length of stay (days) 7 (4, 12)
Country of treatment
 Sierra Leone 290 (68.4)
 Liberia 134 (31.6)
Rapid diagnostic test for malaria results
 Positive 48 (11.3)
 Negative 195 (46.0)
 Not Tested 181 (42.7)
Cycle threshold value /viral load
 ≥22 (Low Viral Load) 122 (28.8)
  < 22 (High Viral Load) 159 (37.5)
 Missing 143 (33.7)
Treatments received in the first 48 hours of care
 Artemether-lumefantrine 376 (88.7)
 ORS 373 (88.0)
 Cefixime 360 (84.9)
 Multivitamins 261 (61.6)
 Ondansetron 111 (26.2)
 Vitamin C 383 (90.3)
 Zinc Sulphate 22 (5.2)
 Paracetamol 399 (94.1)
 Vitamin A 330 (77.8)
Signs & symptoms in the first 48 hours of care
 Abnormal Bleeding 122 (28.8)
 Coma 6 (1.4)
 Diarrhea 298 (70.3)
 Dysphagia 171 (40.3)
 Dyspnea 135 (31.8)
 Jaundice 25 (5.9)
 Anorexia 283 (66.7)
 Abdominal Pain 265 (62.5)
 Vomiting 254 (59.9)
  1. *Values represent mean with standard deviation
  2. Values represent median with interquartile range